Proteasome inhibitors as anti-cancer agents

Anti-Cancer Drugs

Volumn 11, Issue 6, 2000, Pages 407-417

  Murray, R Z ^a   Norbury, C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Inhibitor; Proteasome; Ubiquitin

Indexed keywords

ACLARUBICIN; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; TRANSCRIPTION FACTOR; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYSTEINE ENDOPEPTIDASES; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 0033864137     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200007000-00001     Document Type: Review

References (110)

1. The ubiquitin-proteasome pathway: On protein death and cell life
2. The ubiquitin system
3. Ubiquitin system: Selectivity and timing of protein destruction
4. The 26S proteasome: A molecular machine designed for controlled proteolysis
5. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells
6. The 19 S multicatalytic 'prosome' proteinase is a constitutive enzyme in HeLa cells
7. The multicatalytic proteinase complex (proteasome): Structure and conformational changes associated with changes in proteolytic activity
8. Use of serine-protease inhibitors as probes for the different proteolytic activities of the rat liver multicatalytic proteinase complex
9. Peptidylglutamyl-peptide hydrolase activity of the multicatalytic proteinase complex: Evidence for a new high-affinity site, analysis of cooperative kinetics, and the effect of manganese ions
10. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
11. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 a resolution
12. Proteasome from Thermoplasma acidophilum: A threonine protease
13. The proteasome
14. The proteasome, a novel protease regulated by multiple mechanisms
15. The proteasome activator 11 S REG (PA28) and class I antigen presentation
16. The regulatory particle of the Saccharomyces cerevisiae proteasome
17. Regulatory subunit interactions of the 26S proteasome, a complex problem
18. The base of the proteasome regulatory particle exhibits chaperone-like activity
19. Functional analysis of the proteasome regulatory particle
20. The 26S proteasome of the fission yeast Schizosaccharomyces pombe
21. Recognition of the polyubiquitin proteolytic signal
22. Monoubiquitin carries a novel internalization signal that is appended to activated receptors
23. Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMPT, LMP2, and MECL1 and changes in properties and specificity
24. Novel dipeptide aldehydes are proteasome inhibitors and block the MHC-I antigen-processing pathway
25. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells
26. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules
27. Proteolysis and class I major histocompatibility complex antigen presentation
28. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro
29. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
30. The major substrates for TAP in vivo are derived from newly synthesized proteins
31. Proteasome inhibitors: Valuable new tools for cell biologists
32. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
33. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme
34. A giant protease with potential to substitute for some functions of the proteasome
35. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antinflammatory activity
36. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells
37. Apoptosis induction resulting from proteasome inhibition
38. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome
39. Proteasome inhibitors: A novel class of potent and effective antitumor agents
40. The proteasome inhibitor PS-341 in cancer therapy
41. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
42. Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide
43. Cell cycle regulation by the ubiquitin pathway
44. The ubiquitin-proteasome pathway in cancer
45. Principles of CDK regulation
46. Proteasome-dependent regulation of p21WAF1/CIP1 expression
47. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
48. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
49. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation
50. SCF and Cullin/Ring H2-based ubiquitin ligases
51. Subunits and substrates of the anaphase-promoting complex
52. Universal control mechanism regulating onset of M-phase
53. Proteolysis and the cell cycle: With this RING I do thee destroy
54. Regulation of the APC and the exit from mitosis
55. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer
56. Expression of cell-cycle regulators p27(Kip1) and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
57. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
58. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
59. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells
60. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
61. p53-Dependent induction of apoptosis by proteasome inhibitors
62. Induction of apoptosis by cancer chemotherapy
63. Caspases and caspase inhibitors
64. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in rumor survival and progression
65. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage
66. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
67. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability
68. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
69. Regulation of Mdm2-directed degradation by the C terminus of p53
70. 1 arrest
71. 2/M progression
72. Mdm2: The ups and downs
73. The role of the E6-p53 interaction in the molecular pathogenesis of HPV
74. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
75. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
76. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
77. Control of gene expression by proteolysis
78. The NF-kappa B and I kappa B proteins: New discoveries and insights
79. Multiple signals converging on NF-kappaB
80. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NFkB
81. The Rel/NF-kappaB signal transduction pathway: Introduction
82. The beginning of the end: I-kappa B kinase (IKK) and NF-kappaB activation
83. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B
84. Role of NF-κB in p53-mediated programmed cell death
85. Induction of apoptosis in fibroblasts by c-myc protein
86. Apoptotic cell death induced by c-myc is inhibited by bcl-2
87. Mediation of c-Myc-induced apoptosis by p53
88. AP-1: One switch for many signals
89. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells
90. Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines
91. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells
92. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain
93. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis
94. Proteasomal turnover of p21(Cip1) does not require p21(Cip1) ubiquitination
95. Retrograde protein translocation: ERADication of secretory proteins in health and disease
96. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum
97. 2 homeostasis
98. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
99. The proteasome is involved in angiogenesis
100. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit
101. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy
102. PML is essential for multiple apoptotic pathways
103. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance
104. A combination of retinoic acid and proteasome inhibitors for the treatment of leukemias is potentially dangerous
105. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells
106. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis
107. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
108. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells
109. New approaches to cancer therapies
110. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase